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Abstract
Von Hippel-Lindau (VHL) disease is an autosomal dominant rare tumor syndrome characterized by high penetrance. VHL 
mutation carriers develop numerous manifestations in multiple organs during life. The natural course of development of new 
and growth of existing VHL-related manifestations is still unclear. In this study we aimed to gain insight into the development 
of subsequent manifestations in VHL disease. We retrospectively scored each new VHL-related manifestation as detected by 
standard follow-up (retina, central nervous system, kidneys and pancreas, excluding adrenal and endolymfatic sac manifesta-
tions) in 75 VHL mutation carriers. The Kaplan–Meier method was used to plot the cumulative proportions of all consecutive 
manifestations in each organ against age. The cumulative average number of manifestations in all organs during life was 
calculated by summating these cumulative proportions. Poisson model parameters were used to calculate average time to 
the detection of consecutive VHL manifestations in each organ. Consecutive VHL-related kidney and retina manifestations 
during life occur linearly according to Poisson distribution model. The total number of VHL manifestations rises linearly, 
with an average of seven VHL-related lesions at age 60 years. The incidence of consecutive VHL-related manifestations is 
constant during life in VHL mutation carriers. Our data is consistent with the notion that somatic inactivation of the remain-
ing allele (Knudson’s “two-hit” hypothesis) is the determining factor in developing new VHL-related manifestations.
Keywords Von Hippel-Lindau disease · VHL-related manifestations · Disease progression · Surveillance
Introduction
Von Hippel-Lindau disease (VHL) is a rare inherited tumor 
syndrome with an incidence of 1 in 39,000 to 1 in 91,000 
and a penetrance of > 80% by age 60 [1, 2] and approaching 
100% by age 75 [3, 4]. Affected individuals develop multiple 
VHL-related manifestations during life including heman-
gioblastoma in the central nervous system (CNS) and the 
retina, clear cell renal cell carcinomas (RCC), pheochromo-
cytomas, neuroendocrine pancreatic tumors, and endolym-
phatic sac tumor. Cysts in the kidney and pancreas are also 
frequently found in VHL disease, whereas cystadenomas in 
the epididymis and broad ligament are less common [3, 4].
Growth of existing lesions and development of new mani-
festations both indicate progressive VHL disease. Regular 
surveillance of VHL mutation carriers to detect new or grow-
ing lesions consists of ophthalmologist consultation, imag-
ing (Magnetic Resonance Imaging (MRI) or ultrasound) of 
CNS and abdomen, and urine and plasma biochemistry [3, 
5]. The natural course of VHL- related manifestations is 
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based on clinical observations and is still a matter of discus-
sion; several pathophysiological and (epi)genetic factors are 
suggested to play a role. Two studies show heterogeneous 
tumor growth behavior in RCC, without correlation between 
initial tumor size and growth rate [6, 7]. Tumor formation 
and growth in RCC is influenced by the extracellular matrix, 
tumor vasculature and immune cells [8], but also secondary 
genetic events play a role [9]. Recently a high-resolution 
genome-wide view of chromosomal changes in sporadic 
hemangioblastoma identified 23 candidate genes beyond 
VHL for hemangioblastoma pathogenesis [10].
The characteristic “stuttered” growth (alternate slow/
rapid growth) that is observed in CNS hemangioblastomas 
has not yet been explained [11, 12]. In addition, three case 
series generated contradicting findings regarding the influ-
ence of pregnancy on growth of CNS hemangioblastomas 
in VHL mutation carriers [13–15]. Interestingly, evalua-
tion of CNS hemangioblastomas in VHL patients showed a 
faster growth rate of existing lesions in males, symptomatic 
tumors and tumors associated with cysts [16]. Lonser et al. 
also demonstrate an increased number of CNS tumors per 
year at a younger age (12–20 years). In contrast, another 
study found the highest rate of new CNS hemangioblastomas 
development at age 30–34 years [17]. The working hypoth-
esis is that, as a classic tumor suppressor gene, VHL will 
acquire a somatic mutation in the wild-type allele, leading 
to early tumor development [18].
The way VHL disease progression is defined either 
growth of existing lesions or development of new manifes-
tations, may be important in acquiring a better understanding 
of the natural course of the disease. The aim of this study 
is to gain insight into disease progression in VHL patients 
by focusing on organ-specific serial VHL-related manifesta-
tions. We evaluated the number of subsequent organ mani-
festations diagnosed during life and analyzed whether the 
increase of new manifestation is linear according to the Pois-
son model [19, 20], in accordance with Knudson’s “two-hit” 
hypothesis. If new subsequent VHL-related manifestations 
arise linearly according to the Poisson model, these new 
lesions should occur with a fixed mean interval per organ 
system during life in all VHL patients.
Methods
Patients
All VHL mutation carriers of 18 years or older who under-
went surveillance according to Dutch VHL guidelines [21] 
between 1972 and 2012 in the VHL expertise centers Uni-
versity Medical Center Groningen (UMCG) and University 
Medical Center Utrecht (UMCU) were included. A VHL 
mutation carrier was defined as an individual with either a 
genetically confirmed VHL mutation or the presence of clini-
cal VHL disease. A patient is clinically diagnosed with VHL 
when having two or more CNS hemangioblastomas, a typi-
cal CNS hemangioblastoma(s) and visceral lesion(s) or as 
one typical VHL-related manifestation and a first degree rel-
ative with genetically or clinically proven VHL disease [4]. 
Patients with VHL disease type 1 (including all typical VHL 
manifestations except pheochromcytoma) and type 2 A and 
B (exhibiting all typical VHL-related manifestations with 
low-2 A- and high-2B- risk for RCC) were included. Patients 
with VHL-disease subtype 2C (pheochromocytoma only) 
were excluded. The Dutch surveillance protocol consists 
of biannual MRI of the central nervous system (including 
spinal cord since 1991), annual ophthalmologist consulta-
tion and annual imaging of the abdomen; since 1985 annual 
abdominal ultrasound (at the UMCU and since 1990 at the 
UMCG) and since 2010 abdominal MRI biannual and if 
necessary abdominal ultrasound in alternate years. Intervals 
in surveillance were irrespective of detection of new VHL-
related manifestations, but in case of new manifestations, 
lesion growth or the suspicion of malignancy the frequency 
was increased by repeating the procedure after 4–6 months 
and if stable after 1 year. Interim examinations or additional 
imaging was performed if the carrier developed symptoms. 
Annual plasma and/or urinary assessments of metanephrines 
were performed to detect a pheochromocytoma.
Data collection procedures
Clinical data of 75 VHL mutation carriers were retrospec-
tively retrieved from electronic and written patient records. 
Data were stored in an anonymous database with unique 
codes protecting patient identity. The codes were only held 
by three data managers. Therefore, according to Dutch law 
no further Institutional Review Board approval was required. 
Reports from the Department of Clinical Genetics were used 
for information on genealogy. If the diagnosis was based on 
clinical features preceding an imaging-based diagnosis, the 
first date of diagnosis was defined when the VHL lesion was 
confirmed by imaging.
Detection of new VHL‑related manifestations
For this study we evaluated retinal hemangioblastomas, CNS 
hemangioblastomas (cerebral and spinal cord), and kidney 
(complex cysts and RCC) and pancreatic lesions (including 
cysts or and neuroendocrine pancreatic tumors). New related 
VHL manifestations asymptomatic as well as symptomatic 
were defined as either a new retinal angioma reported by 
the ophthalmologist, a new hemangioblastoma larger than 
1 cm reported in the CNS-MRI (cerebral and spinal cord), 
a new kidney lesion described in the report of the MRI or 
abdominal ultrasound (complex cysts and renal RCC) and 
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a new pancreatic lesion reported in the MRI or abdominal 
ultrasound (including cysts and neuroendocrine pancreatic 
tumors or cystadenomas) regardless the symptoms. Heman-
gioblastomas smaller than 1 cm were excluded. All mani-
festations of hemangioblastoma after neurosurgery were 
included, for it was sometimes difficult to distinguish recur-
rent and new lesions. New renal tumors were scored after 
partial or total nephrectomy, however not used in the cal-
culations, because the patients were censored after surgery, 
based on the expectable reduction of pick-up rate.Patients 
who underwent radical bilateral nephrectomy were excluded 
after the second nephrectomy. Pheochromocytomas were not 
included in this analysis because adrenalectomy prevented a 
second manifestation in the adrenal gland.
Statistical analysis
The Poisson distribution expresses the probability of a given 
number of events occurring in a fixed interval of time or 
space assuming that the events occur with a known constant 
rate and independently of the time since the last event. In 
patients with VHL born with a germline mutation (i.e. the 
first hit) on chromosome 3, the ‘second’ hit resulting in a 
somatic mutation on the other, not affected gene on other 
chromosome 3 is the event that marks the start of an organ 
manifestation.
Poisson distribution model parameters per organ, based 
on the age of appearance of first organ-specific VHL-related 
manifestation, were calculated as described previously [18, 
22]. Linear regression analysis of natural logarithm of 
1-cumulative proportion (ln(1-cumulative proportion)) ver-
sus age was carried out to estimate the average incidence 
k (the organ specific hit rate) of tumor formation from the 
regression coefficient (= −k). The average time between two 
subsequent hits with its Standard Error (S.E.) was derived 
from the inverse of k and its S.E.). The average time between 
a first hit and detection of first VHL-related manifestation 
(delay) was assessed from the intercept of the ln(1-cumu-
lative proportion) with the age axis. The S.E. of delay was 
defined by the S.E. around the regression line divided by 
the regression coefficient k. The median age of first mani-
festation was defined as the age at which half of the carriers 
experienced a first manifestation. Cumulative proportions 
below the 5% level were excluded from the regression analy-
sis because of the sloping edge caused by the variance of 
delay [22]. The hit rate and delay between hit and appear-
ance of a VHL manifestation for each organ were used to 
design Poisson distribution models predicting age of con-
secutive new manifestations. The mean time in years for an 
organ manifestation means that the first organ manifestation 
(after the first somatic mutation in that specific organ, i.e. 
the second hit) occurs on average that age of life (with of 
course a range of birth until death). The delay of an organ 
manifestation denotes the average time in years the tumor 
development takes before can be visualized by imaging. It 
must be realized that the moment of the detection by sur-
veillance also has a window of 1 to 2 years based on the 
surveillance intervals.
For each organ the observed consecutive lesions were 
plotted against age in a Kaplan–Meier curve. The cumulative 
average number of VHL-related manifestations per organ is 
shown by the summation of these graphs. The cumulative 
average number of manifestations in all organs during life 
was calculated by summating the graphs of all organs.
Results
Patients
The characteristics of all 75 VHL mutation carriers and their 
manifestations are shown in Table 1. The median follow-up 
time was 19 years (range 1–41 years). Seven VHL mutation 
carriers died during follow-up; six because of VHL-related 
manifestations. The VHL gene mutations found in the study 
population covered all three exons of the VHL gene. A total 
of 342 lesions in the four organ systems (retina, CNS, kid-
ney, pancreas) were included in this analysis (Supplementary 
Table 1).
Incidence of consecutive VHL‑related manifestations 
per organ
Retinal manifestations
The average time between two subsequent hits for the 
retina was 39.4 years, with a delay after the second hit of 
12.4 years (S.E. 2.83); age at median first manifestation was 
39.9 years (Table 2). About 75% of VHL mutation carriers 
were diagnosed with at least one retinal angioma and 10% 
with at least 3 retinal angiomas (Fig. 1a). The increase in 
number of retinal angiomas was linear, with an average of 1 
retinal angioma per VHL carrier at age 50 (Fig. 1b).
CNS manifestations
The average time between two subsequent hits resulting in 
CNS hemangioblastoma was 21.1 years, with a delay of 
18.1 years (S.E. 2.25); age at median first manifestation was 
31.3 years (Table 2). Almost every VHL mutation carrier 
was diagnosed with at least one CNS hemangioblastoma and 
20% of the patients 5 or more lesions (Fig. 1a). Observed 
consecutive CNS hemangioblastomas arose progressively 
earlier than predicted by the Poisson model, starting around 
age 20. The apparent incidence of new CNS manifestations 
increased with 15% after the first lesion was detected. By the 
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age of 50, an average of two CNS hemangioblastomas were 
detected (Fig. 1b).
Hemangioblastomas in the cerebellum and spinal cord 
were analyzed together as one organ system, defined as CNS 
hemangioblastomas. Therefore, the hit rate and delay in this 
study are slightly different from the earlier reported param-
eters (Kruizinga 2013).
Kidney manifestations
The average time between two subsequent hits of the kidney 
was 11.4 years, with a delay of 23.6 years (S.E. 2.71); age at 
median first manifestation was 31.5 years (Table 2).
Almost all VHL mutation carriers were diagnosed with 
at least one VHL-related kidney manifestation and 40% of 
all VHL patients develop at least 3 kidney lesions (Fig. 1a). 
By the age of 50, VHL patients develop an average of 2 kid-
ney manifestations (Fig. 1b). The increase in the number of 
kidney lesions was linear up to 50 years, but at higher ages, 
was lower than expected.
Table 1  Characteristics of VHL mutation carriers
SB Southern blot removes exon 1 no further details available, HBr retinal hemangioblastoma, HBc cerebellar hemangioblastoma, HBsc spinal 
cord hemangioblastoma, RCC renal cell cancer, pNET pancreatic neuroendocrine tumor, Pheo, pheochromocytoma, Cr renal cyst, Cp pancreatic 
cyst, FU follow up







 c.208G > A 1 (1%) 1 20 HBr
 c.-213-?_463 + ?del 4 (5%) 1 45 (38–48) HBr, HBc, HBsc, RCC, PNET, Cr, Cp
 c.241C > T 2 (3%) 2a/b 47 (34–59) HBr, HBc,HBsc, RCC, PNET, Pheo, Cr
 c.259_260-insA 1 (1%) 1 42 HBr, HBc,HBsc, RCC, Cr, Cp
 c.277G > A 2 (3%) 2a/b 48 (35–60) HBr, HBsc, Pheo, Cr, Cp
 c. 89_297del 25 (33%) 1 40 (17–70) HBr, HBc,HBsc, RCC, PNET, Cr, Cp
 c.340 + 1G > A 1 (1%) 1 32 HBr, HBc, HBsc, RCC, Cr, Cp
 c.341-59_341-14del 2 (3%) 2a/b 52 (33–67) HBr, HBc, RCC, Pheo, Cr, Cp
 c.358A > G 1 (1%) 1 15 HBsc
 c.407T > C 1 (1%) 1 41 HBc, HBsc, RCC, Cr, Cp
 c.462A > C 1 (1%) 2a/b 71 HBc, Pheo. Cr
 c.497T > C 1 (1%) 2a/b 27 PNET, Pheo
 c.499C > T 1 (1%) 2a/b 43 HBr, HBsc, RCC, Pheo, Cr
 c.500G > A 11 (15%) 2a/b 45 (21–65) HBr, HBc,HBsc, RCC,pNET, Pheo, Cr, Cp
 c.509T > A 15 (20%) 2a/b 45 (16–71) HBr, HBc,HBsc, RCC, pNET, Pheo, Cr, Cp
 c.565delG 1 (1%) 1 30 HBc, Cr
 c.463 + 2T > C p.(?) 1 (1%) 1 31 HBr, HBc, HBsc, RCC, Cr
 c.464-3C > T 1 (1%) 1 63 HBr, HBc, HBsc, RCC, Cr
 Rearrangement SB 1 (1%) 1 25 HBr, HBc, HBsc, Cr, Cp
 Unknown 1 (1%) 1 44 HBr, HBc, HBsc, RCC, Cr, Cp
 Nothing found 1 (1%) 1 40 HBr, HBc, Cr
VHL-phenotype:
 Phenotype 1 40 (53%)
 Phenotype 2a/b 35 (47%)
Mean FU in years 19 (0–45)
Table 2  Poisson model parameters in VHL mutation carriers
CNS central nervous system including cerebellum and spinal cord, 
TBH time between hits; Delay, delay between second hit and manifes-
tation, AMF age at median first manifestation
TBH (years) Delay (years) SE (years) AMFM (years)
Retina 39.4 12.4 2.83 39.9
CNS 21.1 18.1 2.25 31.3
Kidney 11.4 23.6 2.71 31.5
Pancreas 33.6 18.2 1.2 41.7
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Fig. 1  Predicted cumulative proportions of consecutive VHL-related 
manifestations for each organ (a, b, c, d) and Lifelong cumulative 
lesions in VHL mutations carriers during life (e, f, g, h) using the 
Poisson model (grey lines) compared to observed lesion counts dur-
ing life (black lines) in retina, CNS, kidney and pancreas
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Pancreas manifestations
The average time between two subsequent hits for the pan-
creas was 11.4 years, with a delay of 18.2 years (S.E. 1.2); 
age at median first manifestation was 41.7 years (Table 2). 
The proportion of VHL patients diagnosed with a second 
pancreatic lesion was about 50% of the predicted propor-
tion by Poisson (Fig. 1a). 80% of all VHL mutation carriers 
will be diagnosed with 1 pancreatic manifestation during 
their life and 20% with 2 lesions. The increase in number of 
pancreatic manifestations is linear at first, as predicted, but 
declined as age advanced (Fig. 1b).
Cumulative number of VHL‑related manifestations 
during life
The increase in predicted and observed cumulative average 
numbers of all VHL manifestations is shown in Fig. 2. Until 
the age of 60 years the increase is as predicted by the Pois-
son model. After 60 years the predicted number of lesions 
were slightly higher than the number reported. VHL muta-
tion carriers developed an average of seven VHL lesions by 
the age of 60.
Discussion
In this study we aimed to gain insight into VHL disease 
activity with regard to the incidence of new organ-specific 
manifestations regardless if these lesions were symptomatic 
or asymptomatic. Using the Poisson model parameters 
derived from the observed data of first manifestation in each 
specific organ, predictions of age at diagnosis of new or con-
secutive VHL-related manifestations in these organs were 
made, as well as the total average number of manifestations 
per carrier during life. These predictions were compared 
with the clinical data in the records of all included VHL 
patients.
We conclude that consecutive VHL-related kidney and 
retina manifestations during life occur linearly according to 
the Poisson distribution model. Consecutive CNS heman-
gioblastomas were detected earlier than predicted according 
to the Poisson distribution and the second pancreatic lesion 
occurred later than predicted by the Poisson model. The 
total systemic number of VHL manifestations rises linearly, 
with an average of seven VHL-related manifestations at age 
60 years. Our findings confirm previous knowledge that 
surveillance for VHL disease should be lifelong. In addi-
tion we show that the occurrence of consecutive of VHL 
manifestations occurs linear. So, a short interval between 
manifestations in a patient does not implicate a different, 
more aggressive change of VHL disease.
It should be emphasized that this study is retrospective 
and based on the report of events in patient records. Thus, 
for CNS manifestations for example, we only accounted for 
the reported incidence of indication for neurosurgical inter-
vention of lesions larger than 1 cm. As such, we did not 
differentiate whether the lesion was new or recurrent and 
we ignored smaller lesions that did not have indication for 
intervention. Likewise, the records of pancreatic lesions in 
many cases reported only the presence or absence of cysts, 
as the number of observed lesions was often not reported 
due to its limited relevance in daily practice.
Observed manifestations in the kidney and the retina 
arose linearly with age after an organ-specific delay as 
expected from the Poisson model. These real-world data 
support the notion that consecutive manifestations occur 
with fixed intervals without any age-related variance until 
the age of 60, after which mortality progressively reduces 
the observed incidence to below model-expected values. 
Similarly, linear relation between age and indication for 
surgery was also observed in CNS lesions. However, new 
lesions were observed about 15% more frequently than pre-
dicted, suggesting that about 15% of second and consecutive 
indications for surgery were likely recurrences of incom-
pletely resected prior lesions, typically observed within a 
year after treatment. In contrast, the expected linear relation 
between age and manifestations in the pancreas was only 
present for the first manifestation. This incongruity might 
be attributable to the fact that only about half of the records 
accurately reported the number and nature of additional 
lesions, whereas the other half only indicated the presence 
of unspecified cysts.
Fig. 2  Average cumulative number of VHL-related manifestation 
during life in VHL mutation carriers summated for all organs; Pois-
son model (grey line) versus observed data (black line)
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At first glance, our results seem to show discrepancies 
with the Danish VHL study [17] and the American CNS 
study [16]. Binderup et al. showed that the rate of new tumor 
formation was highest for retinal lesions in teenage years and 
was highest for cerebellar hemangioblastomas during the 
fourth decade of life. The rate of new tumor development 
for all VHL manifestations was highest at age 30–34 years 
with 0.4 new lesions per year. De facto these data are very 
similar to our results; the delay for retinal lesions to become 
manifest reaches to the early teenage years while for CNS 
lesions this delay is somewhat longer, whereas the maximum 
rate for all manifestations is reached only after the first mani-
festation of kidney lesions at about 25 years of age. Lonser 
et al. [16] reported not only on CNS lesions with indication 
for surgery, but also much smaller ones. They observed the 
increase in CNS manifestations between 12 and 20 years of 
age, indicating that the delay of detection of small lesions is, 
expectably, shorter than for the larger ones needing surgery. 
Notably, Lonser et al. also show that most of the smaller 
lesions never reach the size for indicated intervention and 
thus the rate of formation of CNS lesions is much higher in 
their study.
According to our results new VHL manifestations 
develop at a constant rate per organ system during life and 
are therefore the result of random somatic genetic insults. 
Over 1850 germline and somatic mutations are published 
worldwide in the VHL gene located in the p25 region of 
chromosome 3 [23, 24]. According to Knudson’s two-hit 
hypothesis, the start of tumorgenesis occurs as a result of 
biallelic loss of a tumor suppressor gene [19] and confirmed 
by Maher [25], who showed that both cerebellar hemangio-
blastoma and renal cell carcinoma in VHL disease followed 
the same mutation model. Although biallelic VHL inactiva-
tion and the resulting activation of HIF and its targets seem 
to be necessary for tumor development, other activating fac-
tors are also needed for initiation of tumor progression [19]. 
Loss of the VHL wild-type allele results from deletions or 
point mutations [26–28], although mutations seem not to 
be restricted to the 3p25.3 region [9]. On the other hand, 
growth of existing VHL lesions seems even more complex. 
The increase in size of the solid and/or cystic components 
may be the result of several local pathophysiological and 
(epi)genetic factors over time.
Although not fully understood, Nordstrom [29] described 
the spectrum of mutation types and the clinical spectrum, 
without the understanding how VHL mutations influence 
phenotypes. However, these data may be supportive for us 
to be capable to identify VHL mutations with the intent to 
inform the patient about possible outcome and to modify and 
optimize therapeutic regimen.
A limitation of our study is the retrospective design where 
we were unable to evaluate growth of individual lesions over 
time. Therefore we only studied new manifestations. This 
limitations resulted in the discrepancy between the observed 
number of pancreas and CNS lesions compared to the Pois-
son distribution, based on the underreporting of pancreas 
cysts and the difficulty in discrimination between a new 
or a recurrent lesion. Furthermore, there was systematic 
underestimation of new kidney lesions > 50 years age, for 
two reasons. Firstly, no adjustment was made for partial or 
unilateral nephrectomy in some patients during follow-up. 
And secondly, in some patients existing cysts increased in 
volume to such an extent, that it became virtually impossible 
to recognize any new lesions, reported as “complex cysts”. 
Manifestations in the retina as observed arose linearly with 
age after the organ-specific delay, as expected from the 
Poisson model. We conclude that consecutive manifesta-
tions occurred with fixed intervals without any age-related 
variance until the age of 60, after which mortality progres-
sively reduces the observed incidence to below model-
expected values. Kidney manifestations were also linear up 
to 50 years, but thereafter dropped to fewer than expected 
due to partial and radical nephrectomy, obfuscation of new 
lesions due to complex cysts, and age-related mortality.
Collectively, our data support continue standard surveil-
lance of VHL mutation carriers lifelong to find new manifes-
tations. To date, we have very little data regarding the extent 
and manner in which environmental and (epi)genetic factors 
contribute to the growth of an existing lesion; research in 
these areas will lend novel insights into the natural course 
of disease in VHL. Lastly, because fast growing lesions 
may give rise to symptoms, loss of function and the need 
for immediate intervention, we encourage all VHL health 
care providers to uniformly report the development of new 
lesions and growth of existing lesions in patient’s medical 
records.
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